Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:38pm, Thursday, 18'th Mar 2021
SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q4 2020 Results - Earnings Call Transcript
09:40pm, Thursday, 11'th Mar 2021
Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q4 2020 Results - Earnings Call Transcript
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
04:01pm, Thursday, 11'th Mar 2021
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today prov
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
05:33pm, Monday, 22'nd Feb 2021
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics: Improving Outcomes In 'Standard Of Care' Chemo
07:47pm, Tuesday, 16'th Feb 2021
Oncternal is one of the oldest companies in the ROR1 oncology space, a field fraught with recent acquisitions. Almost every other player in the ROR1 space has been scooped up by big pharma players, bu
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
12:07pm, Friday, 12'th Feb 2021
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
Oncternal: Solid Data In Tough-To-Treat Cancer
08:00am, Sunday, 31'st Jan 2021
Oncternal has solid data for cirmtuzumab+ibrutinib in MCL and CLL. It has cash it says is enough for 2 years.
Oncternal Therapeutics: Recent Success Points To A Bright Future
01:50pm, Friday, 29'th Jan 2021
Oncternal has potential winner with cirmtuzumab in mantle cell lymphoma. A potential pediatric review voucher for TK216 in Ewing sarcoma alone is worth $80-150 million.
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
04:01pm, Thursday, 28'th Jan 2021
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology
Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
04:01pm, Monday, 14'th Dec 2020
SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
11:50pm, Wednesday, 09'th Dec 2020
SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
06:08pm, Wednesday, 09'th Dec 2020
SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
11:00pm, Tuesday, 17'th Nov 2020
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
05:28pm, Tuesday, 17'th Nov 2020
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
